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Abstract
We have previously shown that krill oil (KO), more efficiently than fish oil, was able to downregulate the
endocannabinoid system in different tissues of obese zucker rats.
We therefore aimed at investigating whether an intake of 2 g/d of either KO or menhaden oil (MO), which
provides 309 mg/d of EPA/DHA 2:1 and 390 mg/d of EPA/DHA 1:1 respectively, or olive oil (OO) for four weeks, is
able to modify plasma endocannabinoids in overweight and obese subjects.
The results confirmed data in the literature describing increased levels of endocannabinoids in overweight and
obese with respect to normo-weight subjects. KO, but not MO or OO, was able to significantly decrease 2-
arachidonoylglycerol (2-AG), although only in obese subjects. In addition, the decrease of 2-AG was correlated to
the plasma n-6/n-3 phospholipid long chain polyunsaturated fatty acid (LCPUFA) ratio. These data show for the
first time in humans that relatively low doses of LCPUFA n-3 as KO can significantly decrease plasma 2-AG levels in
obese subjects in relation to decrease of plasma phospholipid n-6/n-3 LCPUFA ratio. This effect is not linked to
changes of metabolic syndrome parameters but is most likely due to a decrease of 2-AG biosynthesis caused by
the replacement of 2-AG ultimate precursor, arachidonic acid, with n-3 PUFAs, as previously described in obese
Zucker rats.
Introduction
The endocannabinoid system is deeply involved in the
regulation of the homeostasis of body composition by
regulating food intake and energy expenditure. An over-
active endocannabinoid system was suggested to contri-
bute to increased fat mass and to several features of
metabolic syndrome [1]. In fact, an increase of ananda-
mide (AEA) and 2-arachidonoylglycerol (2-AG) in over-
weight and obese subjects has been described [2-4].
A therapeutic approach aimed at re-establishing a
physiological tone of the endocannabinoid system
mainly relies on using antagonists of the one of their
targets that is mostly responsible for their metabolic
effects, i.e. the cannabinoid CB1 receptor [5]. However,
it has been shown that the use of these antagonists in
obese individuals is accompanied by psychiatric side
effects such as increased incidence of depression and
anxiety [5,6].
Endocannabinoids are ultimately derived from arachi-
donic acid incorporated in the sn-1 or sn-2 position of
phospholipids, and their biosynthesis was shown to be
affected by dietary fatty acids and in particular by EPA
and DHA [7].
Recently [8], we have shown that in Zucker rats, an
animal model of obesity, both krill oil (KO) and fish oil
similarly increased EPA and DHA plasma levels, with
KO being more effective than fish oil in improving
some parameters of metabolic syndrome such as fatty
liver and fatty heart. This might most probably be
related to the stronger inhibitory effect of KO on endo-
cannabinoid levels in these tissues and, particularly, in
the visceral adipose tissue. In addition, we have recently
reported that administration of 2 g/d of KO or menha-
den oil (MO) for four weeks, significantly increased EPA
and DHA levels in plasma in normal, overweight and
obese subjects [9]. This KO dose provided 216 mg/d
EPA and 90 mg/d DHA, while MO provided 212 mg/d
EPA and 178 mg/d DHA. The International Society for
the Study of Fatty Acids and Lipids (ISSFAL) reported
as a recommendation [10] for cardiovascular health a
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minimum intake of combined EPA and DHA of
500 mg/day, based on several studies showing a signifi-
cant reduction of cardiovascular risk with this dose or
higher. In addition, the effect of n-3 long chain polyun-
saturated fatty acids (LCPUFA) on metabolic syndrome
parameters has been shown to be effective at much
higher doses [11].
To our knowledge, the effect of dietary n-3 fatty acids
on AEA and 2-AG concentrations in human plasma has
never been investigated. This issue is not trivial, since it
is well established that plasma 2-AG levels in obese
individuals strongly correlate with several parameters of
the metabolic syndrome, including visceral adipose tis-
sue, high triglyceride levels, low HDL-cholesterol levels
and indices of insulin resistance. Therefore, in this study
we aimed at verifying whether or not four-week dietary
intake of KO, FO or olive oil (OO), is able to modify
endocannabinoid levels in the plasma of normo-weight,
overweight and obese subjects.
Materials and methods
Study design
This was a 4-week, randomized, double-blind, controlled,
parallel clinical trial conducted at 2 clinical research sites
in the United States (Provident Clinical Research, Bloo-
mington, IN, and Meridien Research, St. Petersburg, FL).
The study included 3 visits: 2 screening/baseline visits
(weeks -1 and 0) and 1 end-of-treatment visit (week 4).
An independent institutional review board, Quorum
Review, Inc. (Seattle, Wash), approved the protocol
before initiation of the study, and written informed con-
sent was obtained from all subjects before protocol-speci-
fic procedures were performed.
Subjects
63 subjects generally healthy men and women, 35 to
64 years of age, with waist circumference of 102 cm or
greater (men) or 88 cm or greater (women) were
included (see Table 1 for demographic and anthropo-
metric characteristics). Pregnant (or those planning to
become pregnant during the study period) and lactat-
ing women were excluded. Volunteers who consumed
fish more than 3 times in the month before screening
were not eligible for enrollment and consumption of
fish and seafood products was prohibited during the
study. Individuals with a self-reported history of dia-
betes, inflammatory bowel disease, pancreatitis, and
gallbladder or biliary disease in the 12 months before
the screening visit were excluded from the study. In
addition, those with a history of cancer (except for
nonmelanoma skin cancer) in the 2 years before
screening or any major trauma or surgical event within
3 months before screening were not enrolled. Volun-
teers were also excluded if they had serum triglycerides
(TG) ≥500 mg/dL, total cholesterol (TC) ≥300 mg/dL,
or uncontrolled hypertension (systolic blood pressure
≥160 mm Hg or diastolic blood pressure ≥100 mm
Hg) at screening. The use of lipid-altering medications
or supplements, non-study-related omega-3 fatty acid
supplements (eg, flaxseed, fish, or algal oils) or omega-
3 fatty acid-enriched or fortified foods, and anticoagu-
lants was prohibited within 2 weeks of screening and
throughout the study.
Study procedures
At baseline, eligible subjects were randomly assigned to
1 of 3 groups: 2 g/d of either KO (Superba krill oil,
Aker BioMarine ASA, Oslo, Norway), MO (Omega-
Pure, Houston, Tex), or olive oil (control). Subjects were
instructed to consume four 500 mg capsules per day,
preferably 2 capsules with each of 2 meals, for 4 weeks.
Four capsules of the KO supplement provided 216 mg/d
EPA and 90 mg/d DHA, and the MO supplement pro-
vided 212 mg/d EPA and 178 mg/d DHA. Stratification
of the subjects has been carried out by BMI values: nor-
moweight BMI <25; overweight 25 < BMI <30; obese
30 < BMI <35.
Further details of the study are described in [9].
Lipid analyses
Total lipids were extracted from plasma using chloro-
form/methanol 2:1 (v/v) [12]. Separation of phospholi-
pids (PL) from total lipids was performed as previously
reported [13]. Aliquots were mildly saponified as pre-
viously described [14] in order to obtain free fatty acids
for HPLC analysis. Separation of fatty acids was carried
out with an Agilent 1100 HPLC system (Agilent, Palo
Alto, Calif., USA) equipped with a diode array detector
as previously reported [15]. N-arachidonoylethanolamine
(anandamide, AEA) and 2-arachidonoylglycerol (2-AG)
were measured as previously described [16].
Table 1 Baseline demographic and anthropometric
characteristics of subjects by treatment group
OO MO KO
(n = 19) (n = 23) (n = 21)
Male, n 3 4 3
Female, n 16 19 18
Normoweight, n, male/female 1/3 1/3 1/6
Overweight, n, male/female 1/6 2/5 1/4
Obese, n, male/female 1/7 1/11 1/8
Age, year, mean ± SEM 47.4 ± 8.5 49.6 ± 8.7 49.4 ± 8.5
Body mass index, kg/m2,
mean ± SEM
30.6 ± 1.3 31.6 ± 0.9 30.1 ± 1.0
Stratification of the subjects has been carried out by BMI values: normoweight
BMI <25; overweight 25 < BMI <30; obese 30 < BMI <35.
There were no significant differences between groups for any variable.
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Statistical analyses
One way ANOVA with the Bonferroni test for post-hoc
analyses was applied to evaluate statistical differences
between groups. Whereas t-student test for paired sam-
ples was applied to detect significant differences
between before and after treatment.
Results
No changes in BMI, waist circumference, glycemia and
insulinemia were detected after any of the treatments
(data not shown).
At baseline, plasma AEA levels were significantly
higher in obese subjects, whereas plasma 2-AG levels
were significantly higher only in overweight subjects
(figure 1). Four week dietary intake of KO was able to
significantly decrease 2-AG, but not AEA, only in the
obese subjects, although a non-statistically significant
trend towards a decrease was observed also in over-
weight subjects (figure 2). By contrast, MO or OO treat-
ments did not modify endocannabinoid levels in either
overweight or obese individuals (figure 2). A significant
correlation between 2-AG levels and the plasma phos-
pholipids n-6/n-3 LCPUFA ratio [(20:4n6+22:5n6
+20:3n-6+22:4n-6)/(20:5n-3+22:6n-3)] was observed only
in obese subjects whose diet was supplemented with KO
(figure 3). No other correlation was found between
endocannabinoids and single plasma phospholipid fatty
acids, or in normo and overweight patients. In addition,
due to the relatively low number of male subjects
recruited, it was not possible to make any statistical ana-
lysis on gender differences in terms of treatment effects
(data not shown).
Discussion
In this pilot study we have confirmed data in the litera-
ture showing that overweight and obese subjects exhibit
increased plasma levels of the endocannabinoids, AEA
and 2-AG [2-4]. In our cohort of subjects, however,
plasma 2-AG levels were increased significantly only in
overweight individuals, whereas AEA levels were
increased significantly only in obese subjects. This find-
ing agrees with previous results suggesting that
increased plasma AEA levels are associated with high
BMI [17], whereas increased plasma 2-AG levels are
associated with high visceral adipose tissue and not
necessarily with high BMI [3,18,19]. It is possible that
the cohort of obese subjects of the present study might
have been characterized by a higher proportion of sub-
cutaneous adipose tissue than in other cohorts pre-
viously investigated. As we did not acquire data on the
adipose distribution in the obese subjects of a present
study, this remains only a speculative hypothesis, to be
specifically addressed in future studies. In addition, fat
distribution in overweight premenopausal women may
be different from that in postmenopausal women and in
men for a given level of waist circumference. Thus, the
small number of subjects in the present study and the
heterogeneous nature of the sample (i.e., men as well as
pre- and postmenopausal women) do not permit a
meaningful assessment of the correlation of 2-AG levels
with visceral fat distribution.
The novel finding of the present study is that KO,
more efficiently than MO, was able to reduce endocan-
nabinoid levels in the plasma despite the fact that the
effects of the two dietary treatments on EPA and DHA
plasma concentrations were comparable and even
slightly lower in the KO group than in the MO group
[9]. Comparable results were obtained in the visceral
adipose tissue, liver and heart of obese Zucker rats [8].
However, in this previous study, 2-AG concentrations
were decreased significantly by KO, and to a smaller
extent by fish oil, only in the visceral adipose tissue.
One possible explanation for the different effects of KO
and fish oil might be, as previously suggested [8], the
more efficient incorporation of n-3 LCPUFAs into visc-
eral adipose tissue phospholipids, and subsequent
decrease in arachidonic acid incorporation associated
with KO supplementation, hence leading to impaired
endocannabinoid biosynthesis.
Thus, it is tempting to suggest that plasma 2-AG
mainly derives from this tissue, possibly because of its
relatively high concentrations in this adipose depot. This
hypothesis is in agreement with the strong correlations
previously described between the amount of visceral adi-
pose tissue and plasma 2-AG levels in overweight and
obese subjects [18,19]. By contrast, in the subcutaneous
adipose tissue of obese animals [20] and obese subjects
with type 2 diabetes [2], 2-AG levels seem to be rather
decreased, indicating that the 2-AG levels in the plasma
cannot be predicted from those in the subcutaneous fat,
and vice versa.
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Figure 1 Baseline Endocannabinoid plasma levels (nM),
anandamide (AEA) left panel; 2-arachidonoylglycerol (2-AG)
right panel, in normoweight subjects (norm) (n = 15),
overweight (OW) subjects (n = 19) and obese subjects (OB)
(n = 29). Error bars depict S.E.M. Different letters denote significant
differences (p < 0.05).
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Figure 2 Endocannabinoid plasma levels (nM) before (pre) and after (post) treatment with different oils. norm = normoweight subjects;
OW = overweight subjects; OB = obese subjects. A and B anandamide (AEA) and arachidonoylglycerol (2-AG) respectively with Krill oil (KO)
treatment (n = 7, n = 5, n = 9 in norm, OW and OB respectively); C and D AEA and 2 AG respectively with menhaden oil (MO) treatment (n = 4,
n = 7, n = 12 in norm, OW and OB respectively); E and F AEA and 2 AG respectively with olive oil (OO) treatment (n = 4, n = 7, n = 8 in norm,
OW and OB respectively). Error bars depict S.E.M. * denotes statistical difference (p < 0.05).
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The positive correlation between 2-AG and the plasma
phospholipid n-6/n-3 LCPUFA ratio, and not with the
absolute plasma phospholipid concentrations of n-3 or
n-6 LCPUFA, suggests that at least 2-AG levels are
strongly influenced by fatty acid metabolism involving
the balance between n-6 and n-3 LCPUFA. Interestingly,
it has been demonstrated that the n-6/n-3 LCPUFA
ratio, rather than absolute values of n-6 and n-3 PUFA,
is correlated to cardiovascular disease [21], which is also
directly associated with many of the metabolic disorders
that positively correlate with plasma 2-AG levels
[3,18,19]. Thus, it is tempting to hypothesize that KO
ameliorates cardiovascular disorders in overweight and
obese subjects, at least in part, by re-establishing a phy-
siological endocannabinoid tone at CB1 receptors, via
decrease of the n-6/n-3 phospholipid LCPUFA ratio
and, hence, reduction of the ultimate biosynthetic pre-
cursors of 2-AG, the up-regulation of which is instead
associated with visceral obesity, dyslipidemia, insulin
resistance and atherogenic inflammation [5]. Since AEA
is derived from AA esterified on the sn-1 position, and
2-AG from that esterified on the sn-2 position in the
phospholipids, and since a reduction of the n-6/n-3
LCPUFA ratio would mostly affect the latter, this
hypothesis, which is also based on the results from our
previous study in Zucker rats, would also explain why
KO only affected 2-AG and not AEA levels in the
plasma. However, in the present study no significant dif-
ferences in lipid metabolism, body weight or metabolic
syndrome parameters were detected among the 3 groups
of dietary treatments [9]. Therefore, the hypothesis that
KO-induced reduction of plasma 2-AG levels may result
in an amelioration of the metabolic dysfunctions asso-
ciated with overweight and obesity will require further
investigation. Even though a recent report [22] showed
that plasma phospholipid n-3 PUFA was inversely asso-
ciated with the metabolic syndrome, the lack of changes
in metabolic syndrome parameters in the subjects that
were administered with KO may suggest that four weeks
of such treatment, and of the consequent KO-induced
inhibition of 2-AG levels, is not sufficient to exert any
beneficial metabolic effects. Indeed, even the direct
antagonism of CB1 with rimonabant (20 mg/day) in
obese subjects starts reducing body weight and amelior-
ating dyslipidemia and insulin resistance only after
2-3 months from the beginning of treatment [5]. More-
over, the lack of effect on triglyceride levels after treat-
ment might be related to the fact that the participants
in the study were normo-lipidemic. The lipid-lowering
property of omega-3 fatty acids such as EPA and DHA
is more pronounced in subjects with elevated triglycer-
ides [23,24].
Future studies will have to investigate whether longer
dietary interventions and higher dietary levels of KO,
apart from still down-regulating the endocannabinoid
system, also improve the metabolic syndrome, thus pos-
sibly representing an alternative to CB1 antagonists/
inverse agonists for the treatment of this disorder.
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